PD-1 analysis on CD28-CD27- CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients

American Journal of Transplantation

Volumn 13, Issue 12, 2013, Pages 3132-3141

  Dirks, J ^a   Tas, H ^a   Schmidt, T ^a   Kirsch, S ^a   Gartner B C ^a   Sester, U ^a   Sester, M ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CD27; CD28; Cytomegalovirus; Monitoring; T cell; Transplantation

Indexed keywords

BASILIXIMAB; CD27 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROGRAMMED DEATH 1 LIGAND 1; STEROID; TACROLIMUS; VALGANCICLOVIR;

ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VIREMIA;

CD27; CD28; CYTOMEGALOVIRUS; MONITORING; T CELL; TRANSPLANTATION;

ADULT; ANTIGENS, CD27; ANTIGENS, CD28; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FLOW CYTOMETRY; HUMANS; KIDNEY TRANSPLANTATION; MIDDLE AGED; PHENOTYPE; POSTOPERATIVE COMPLICATIONS; PROGRAMMED CELL DEATH 1 RECEPTOR; RENAL DIALYSIS; RENAL INSUFFICIENCY; SENSITIVITY AND SPECIFICITY; VIREMIA;

EID: 84888331175     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12480     Document Type: Article

References (32)

1. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2013; 96: 333-360.
2. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329-337.
3. Sester M, Gärtner BC, Sester U., Monitoring of CMV specific T-cell levels after organ transplantation. J Lab Med 2008; 32: 121-130.
4. Walker S, Fazou C, Crough T, et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007; 9: 165-170.
5. Westall GP, Mifsud NA, Kotsimbos T., Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant 2008; 8: 1749-1754.
6. Sester M, Sester U, Gärtner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287-1294.
7. Sester U, Presser D, Dirks J, Gärtner BC, Köhler H, Sester M., PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008; 8: 1486-1497.
8. Brown KE, Freeman GJ, Wherry EJ, Sharpe AH., Role of PD-1 in regulating acute infections. Curr Opin Immunol 2010; 22: 397-401.
9. Khaitan A, Unutmaz D., Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 2011; 8: 4-11.
10. Odorizzi PM, Wherry EJ., Inhibitory receptors on lymphocytes: Insights from infections. J Immunol 2012; 188: 2957-2965.
11. Looney RJ, Falsey A, Campbell D, et al. Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin Immunol 1999; 90: 213-219.
12. Pourgheysari B, Khan N, Best D, Bruton R, Nayak L, Moss PA., The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol 2007; 81: 7759-7765.
13. van de Berg PJ, Griffiths SJ, Yong SL, et al. Cytomegalovirus infection reduces telomere length of the circulating T cell pool. J Immunol 2010; 184: 3417-3423.
14. van Leeuwen EM, Remmerswaal EB, Heemskerk MH, ten Berge IJ, van Lier RA., Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 2006; 108: 3121-3127.
15. van Leeuwen EM, Remmerswaal EB, Vossen MT, et al. Emergence of a CD4+ CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004; 173: 1834-1841.
16. Fletcher JM, Vukmanovic-Stejic M, Dunne PJ, et al. Cytomegalovirus- specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol 2005; 175: 8218-8225.
17. Chamuleau ME, ten Berge IJ, Schellekens PT, Wilmink JM, Hintzen RQ, van Lier RA., Serum levels of soluble CD27 in renal transplant recipients. Transplantation 1992; 54: 932-936.
18. Nakatsuji T., High levels of serum soluble CD27 correlated with renal dysfunction. Clin Exp Med 2003; 2: 192-196.
19. Sester M, Gärtner BC, Sester U, Girndt M, Mueller-Lantzsch N, Köhler H., Is the CMV serologic status always accurate?-A comparative analysis of humoral and cellular immunity. Transplantation 2003; 76: 1229-1231.
20. Ritter M, Schmidt T, Dirks J, et al. Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol 2013; 43: 1099-1108.
21. Derhovanessian E, Maier AB, Hahnel K, et al. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol 2011; 92: 2746-2756.
22. Rentenaar RJ, Gamadia LE, van DerHoek N, et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest 2000; 105: 541-548.
23. Sester M, Sester U, Gartner BC, Girndt M, Meyerhans A, Kohler H., Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13: 2577-2584.
24. La Rosa C, Krishnan A, Longmate J, et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008; 197: 25-33.
25. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-354.
26. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8(+) T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-1202.
27. Urbani S, Amadei B, Tola D, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80: 11398-11403.
28. Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8: 1246-1254.
29. Kaufmann DE, Walker BD., PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009; 182: 5891-5897.
30. Kassu A, Marcus RA, D'Souza MB, et al. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol 2010; 185: 3007-3018.
31. Vali B, Jones RB, Sakhdari A, et al. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010; 40: 2493-2505.
32. Hafler DA, Kuchroo V., TIMs: Central regulators of immune responses. J Exp Med 2008; 205: 2699-2701.